Welcome to LookChem.com Sign In|Join Free

CAS

  • or
(S)-morpholin-2-ylmethanol is a novel chemical compound that features a unique combination of a morpholine group and a methanol group. Morpholine, an organic compound with a six-membered ring containing four carbon atoms, one oxygen atom, and one nitrogen atom, is known for its diverse applications. Methanol, the simplest alcohol with a methyl group linked to a hydroxyl group, is also widely used across various industries. Although specific properties and applications of (S)-morpholin-2-ylmethanol are not extensively documented due to its novelty, the versatility of its constituent groups suggests potential uses in multiple fields.

132073-83-7 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 132073-83-7 Structure
  • Basic information

    1. Product Name: (S)-morpholin-2-ylmethanol
    2. Synonyms: (S)-morpholin-2-ylmethanol;(S)-2-morpholinemethanol;(S)-morpholin-2-ylmethanol hydrochloride;2-MorpholineMethanol, (2S)-;(S)-Morpholin-2-ylMethanol-HCl;(S)-Morpholine-2-methanol;(2S)-Morpholin-2-ylMethanol;(2S)-2-Morpholinemethanol
    3. CAS NO:132073-83-7
    4. Molecular Formula: C5H11NO2
    5. Molecular Weight: 117.14634
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 132073-83-7.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: (S)-morpholin-2-ylmethanol(CAS DataBase Reference)
    10. NIST Chemistry Reference: (S)-morpholin-2-ylmethanol(132073-83-7)
    11. EPA Substance Registry System: (S)-morpholin-2-ylmethanol(132073-83-7)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 132073-83-7(Hazardous Substances Data)

132073-83-7 Usage

Uses

Given the versatility of both morpholine and methanol, (S)-morpholin-2-ylmethanol may find applications in various industries, including but not limited to:
Used in Chemical Synthesis:
(S)-morpholin-2-ylmethanol is used as a building block or intermediate for the synthesis of more complex organic compounds, leveraging the reactivity of both the morpholine and methanol groups.
Used in Solvents:
(S)-morpholin-2-ylmethanol is used as a solvent in various chemical processes, taking advantage of its ability to dissolve a wide range of substances and facilitate reactions.
Used in Pharmaceutical Industry:
(S)-morpholin-2-ylmethanol is used as a pharmaceutical intermediate for the development of new drugs, potentially due to its unique structural features that can be exploited in medicinal chemistry.
Used in Material Science:
(S)-morpholin-2-ylmethanol may be utilized in the development of new materials, such as polymers or coatings, where its chemical properties can contribute to desired material characteristics.

Check Digit Verification of cas no

The CAS Registry Mumber 132073-83-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,2,0,7 and 3 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 132073-83:
(8*1)+(7*3)+(6*2)+(5*0)+(4*7)+(3*3)+(2*8)+(1*3)=97
97 % 10 = 7
So 132073-83-7 is a valid CAS Registry Number.
InChI:InChI=1S/C5H11NO2.ClH/c7-4-5-3-6-1-2-8-5;/h5-7H,1-4H2;1H/t5-;/m0./s1

132073-83-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name [(2S)-morpholin-2-yl]methanol

1.2 Other means of identification

Product number -
Other names Morpholin-2-yl-methanol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:132073-83-7 SDS

132073-83-7Relevant articles and documents

Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER

Tamagnan, Gilles D.,Brenner, Eric,Alagille, David,Staley, Julie K.,Haile, Colin,Koren, Andrei,Early, Michelle,Baldwin, Ronald M.,Tarazi, Frank I.,Baldessarini, Ross J.,Jarkas, Nachwa,Goodman, Mark M.,Seibyl, John P.

, p. 533 - 537 (2007)

A series of reboxetine analogs was synthesized and evaluated for in vitro binding as racemic mixtures. The best candidate (INER) was synthesized as the optically pure (S,S) enantiomer, labeled with iodine-123 and its in vivo binding determined by SPECT im

Radiosynthesis and evaluation of 18F-labeled dopamine D4-receptor ligands

Willmann, Michael,Ermert, Johannes,Prante, Olaf,Hübner, Harald,Gmeiner, Peter,Neumaier, Bernd

, p. 43 - 52 (2020/08/03)

Introduction: The dopamine D4 receptor (D4R) has attracted considerable attention as potential target for the treatment of a broad range of central nervous system disorders. Although many efforts have been made to improve the performance of putative radioligand candidates, there is still a lack of D4R selective tracers suitable for in vivo PET imaging. Thus, the objective of this work was to develop a D4-selective PET ligand for clinical applications. Methods: Four compounds based on previous and new lead structures were prepared and characterized with regard to their D4R subtype selectivity and predicted lipophilicity. From these, 3-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo[2,3-b]pyridine I and (S)-4-(3-fluoro-4-methoxybenzyl)-2-(phenoxymethyl)morpholine II were selected for labeling with fluorine-18 and subsequent evaluation by in vitro autoradiography to assess their suitability as D4 radioligand candidates for in vivo imaging. Results: The radiosynthesis of [18F]I and [18F]II was successfully achieved by copper-mediated radiofluorination with radiochemical yields of 7% and 66%, respectively. The radioligand [18F]II showed specific binding in areas where D4 expression is expected, whereas [18F]I did not show any uptake in distinct brain regions and exhibited an unacceptable degree of non-specific binding. Conclusions: The compounds studied exhibited high D4R subtype selectivity and logP values compatible with high brain uptake, but only ligand [18F]II showed low non-specific binding and is therefore a good candidate for further evaluation. Advances in knowledge: The discovery of new lead structures for high-affinity D4 ligands opens up new possibilities for the development of suitable PET-radioligands. Implications for patient: PET-imaging of dopamine D4-receptors could facilitate understanding, diagnosis and treatment of neuropsychiatric and neurodegenerative diseases.

Novel Hydrazinone-substituted Pyrimidine Derivatives and Use Thereof

-

Paragraph 0114-0116, (2018/05/29)

The present invention relates to a pyrimidine derivative substituted with novel hydrazine or a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition for inhibiting c-Met tyrosine kinase activity and to a pharmaceutical composition for preventing or treating hyperproliferative disorders, which comprise same as an active ingredient. The present invention can be effectively used as a treatment agent for various hyperproliferative disorders related to excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy by efficiently inhibiting c-Met tyrosine kinase activity.

Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors

Kim, Eun-Young,Kang, Seung-Tae,Jung, Heejung,Park, Chi Hoon,Yun, Chang-Soo,Hwang, Jong Yeon,Byun, Byung Jin,Lee, Chong Ock,Kim, Hyoung Rae,Ha, Jae Du,Ryu, Do Hyun,Cho, Sung Yun

, p. 453 - 464 (2016/04/26)

A series of pyridazin-3-one substituted with morpholino-pyrimidine derivatives was synthesized and evaluated as tyrosine kinase inhibitors against c-Met enzyme, and anti-proliferative activities of Hs746T human gastric cancer cell line. Most of compounds exhibited good biological activity, while compound 10, 12a, 14a displayed excellent c-Met enzyme inhibitory activities and Hs746T cell-based activities.

Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors

Kang, Seung-Tae,Kim, Eun-Young,Archary, Raghavendra,Jung, Heejung,Park, Chi Hoon,Yun, Chang-Soo,Hwang, Jong Yeon,Choi, Sang Un,Chae, Chonghak,Lee, Chong Ock,Kim, Hyoung Rae,Ha, Jae Du,Ryu, Dohyun,Cho, Sung Yun

supporting information, p. 5093 - 5097 (2014/12/11)

We report a series of phenyl substituted pyridazin-3-ones substituted with morpholino-pyrimidines. The SAR of the phenyl was explored and their c-Met kinase and cell-based inhibitory activity toward c-Met driven cell lines were evaluated. Described herein

MORPHOLINO COMPOUNDS, USES AND METHODS

-

Paragraph 0172-0175, (2014/06/11)

The invention relates to morpholino-derivatives according to Formula (I) or stereoisomers or pharmaceutically acceptable salts or solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7/s

BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS

-

Paragraph 0195, (2014/09/29)

The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

MORPHOLINO COMPOUNDS, USES AND METHODS

-

Page/Page column 48, (2012/12/13)

The invention relates to morpholino-derivatives according to Formula (I) or stereoisomers or pharmaceutically acceptable salts or solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7/s

Sulfinamides as highly effective amine protecting groups and their use in the conversion of Amino alcohols into morpholines

Fritz, Sven P.,Mumtaz, Amara,Yar, Muhammad,McGarrigle, Eoghan M.,Aggarwal, Varinder K.

experimental part, p. 3156 - 3164 (2011/06/28)

1,2-Amino alcohols have been converted into morpholines by using sulfinamides as temporary protecting/activating groups on the amine. We have developed a procedure for the selective synthesis of monoprotected N-sulfinyl amino alcohols through a double sul

PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE AND PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE COMPOUNDS AND THEIR USE

-

Page/Page column 258-259, (2009/05/29)

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin- 2 - yl -pyridin- 2 -yl -amine and pyrazine - 2 - yl -pyrimidin- 4 - yl -amine compounds of formula (I), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1 ) kinase function The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1. that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or Il inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionisiπq radiation. wherein: -X= is independently -CRA5= or -N=; and the rest of the substituents are as specified in the claims.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 132073-83-7